Search results
Author(s):
Isla S Mackenzie
,
Thomas M MacDonald
Added:
3 years ago
Hypertension becomes more common with increasing age. As we gradually move towards having a higher proportion of elderly people in the population, greater numbers of octogenarians are being treated for hypertension. In this article we describe the main features of hypertension in the elderly and describe some of the particular issues that affect elderly patients. We also discuss the results of…
View more
Author(s):
Roland E Schmieder
Added:
3 years ago
The primary goal in the treatment of hypertensive patients is to achieve the maximum possible reduction in the long-term total risk of cardiovascular (CV) and renal morbidity and mortality. In addition to the lowering of blood pressure (BP) per se, successful realisation of the primary goal of treatment also requires appropriate consideration of co-morbidities.1–3 Although there is some…
View more
Author(s):
Peter M Nilsson
Added:
3 years ago
Some cardiovascular (CV) risk-prone patients are easy to recognise, for example following manifestations of cardiovascular disease (CVD), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) interventions, and they deserve appropriate risk-factor control for secondary prevention, including blood pressure (BP) lowering. However, many other at-risk patients…
View more
Author(s):
Peter M Nilsson
Added:
3 years ago
Some cardiovascular (CV) risk-prone patients are easy to recognise, for example following manifestations of cardiovascular disease (CVD), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) interventions, and they deserve appropriate risk-factor control for secondary prevention, including blood pressure (BP) lowering. However, many other at-risk patients…
View more
Author(s):
Franz H Messerli
,
Georg Noll
,
Lars H Lindholm
,
et al
Added:
3 years ago
Recent evidence supports a central role for calcium channel blockers (CCBs), and in particular the dihydropyridine (DHP) agents, in the treatment of hypertension and cardiovascular disease (CVD). We review here the findings of recent trials, systematic reviews and meta-analyses that rebut those of the single, yet widely-publicised, earlier unfavourable meta-analysis.1 In these latest reports,…
View more
Author(s):
Michel Burnier
Added:
3 years ago
In 2007, the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) published their guidelines for the management of arterial hypertension.1 These guidelines covered in detail all aspects of the management of hypertensive patients, from the diagnosis and detection of early subclinical organ damage to the discussion of the various therapeutic strategies in essential…
View more
Author(s):
Cristina Sierra
,
Antonio Coca
Added:
3 years ago
Hypertension Treatment
The aim of antihypertensive treatment is to reduce the cardiovascular morbidity and mortality associated with high blood pressure (BP) levels by measures aimed at reducing BP levels and minimising the impact of possible associated risk factors or co-morbidities.1–5 This therapeutic goal requires previous cardiovascular risk stratification to assess the global risk of…
View more
Author(s):
Massimo Volpe
,
Giuliano Tocci
,
Francesca Giovannelli
Added:
3 years ago
Cerebrovascular accidents are one of the leading causes of morbidity and mortality worldwide. The World Health Organization (WHO) found that in 1990 stroke accounted for 4.3 million mortalities, the third most common cause of death worldwide. Projecting forward to 2020, the incidence of stroke-related death is expected to rise to 7.7 million per year.
High blood pressure is one of the most…
View more
Author(s):
Zengwu Wang
,
Tom Richart
,
Yu Jin
,
et al
Added:
3 years ago
Stroke is the second most common cause of mortality worldwide.1 Cerebrovascular disease caused an estimated 5.7 million deaths in 2005, with 87% occurring in low- or middle-income countries.2 Without intervention, the global number of stroke deaths will rise to 6.5 million in 2015 and 7.8 million in 2030.2 Blood pressure is the most consistent and powerful predictor of stroke. Hypertension…
View more
Author(s):
Alexandre Persu
,
Fadl Elmula M Fadl Elmula
,
Yu Jin
,
et al
Added:
3 years ago
Renal sympathetic denervation (RDN) has been introduced as a novel approach to treat patients with so-called resistant hypertension.1–3 The first randomised clinical trial showed an impressive 32/12 mmHg fall in blood pressure after six months in the intervention group (n=52) compared to the control group (n=54). However, with the recent publication of the Symplicity HTN-3 study in the US4 the…
View more